(MGNX) MacroGenics, Inc. Business Model Canvas Research

Janssen Biotech, Inc., part of Johnson & Johnson, is a major alliance partner for MacroGenics, Inc., helping advance selected therapeutic programs through shared development work. Large pharma partners like Janssen can bring scale, funding, and late-stage clinical expertise; Johnson & Johnson reported $88.8 billion in full-year 2024 sales, showing the size of the platform backing this kind of collaboration.

• Advances selected programs faster
• Adds capital and development scale
• Uses large pharma trial expertise

MacroGenics uses a broad network of CROs, trial sites, and manufacturing partners to run its antibody pipeline, so execution sits outside the Company. External collaborators support clinical operations, process development, and supply chain work, which is vital in a sector where late-stage trials and GMP manufacturing can drive most cost and timing risk.

• CROs run trial ops and data capture.
• Sites enroll patients and monitor safety.
• Manufacturers support process and supply.
• Partnerships reduce execution bottlenecks.

MacroGenics, Inc. relies on regulatory and quality operations to manage IND filings, NDA/BLA support, safety reporting, and validated quality systems. In biopharma, one missed FDA filing or safety update can stall a trial, so this work is central to approvals, renewals, and partner trust.

• INDs and BLA support
• Fast safety reporting
• Strong quality systems
• Keeps trials moving
• Builds partner confidence

MacroGenics, Inc. uses business development and alliance management to structure partnerships, licenses, and co-development deals that turn antibody assets into cash while sharing R&D risk. Its model has long relied on alliance revenue and milestone payments, including a $325 million upfront deal with Gilead in 2024, to extend reach without funding all development alone.

• Monetize assets through licensing
• Share trial and launch risk
• Expand reach via partners

Founded in 2000, MacroGenics, Inc. depends on R&D and clinical expertise to turn antibodies into data-driven programs. Scientific talent, clinical operations know-how, and translational medicine capability are the human capital that drive execution in a company still centered on development.

• Scientific talent supports target discovery and design.
• Clinical ops know-how keeps trials on track.
• Translational medicine links lab results to patients.

MacroGenics, Inc. is centered in Rockville, Maryland, where its headquarters handles leadership, coordination, and strategic control for the business. That U.S. base anchors the company’s operating model and supports one corporate hub for decision-making, partner management, and oversight.

• Rockville HQ = core control point
• Supports U.S.-based operations
• Enables leadership and coordination

MacroGenics, Inc. uses a multi-indication platform that reaches beyond one tumor type, with programs spanning HIV, type 1 diabetes, and autoimmune disease. That widens its scientific and commercial reach across 3 disease areas and lowers reliance on any single oncology market.

• 3 named non-oncology areas
• Broader addressable market
• Less single-market dependence

MacroGenics, Inc. uses partnerships to advance its pipeline with shared risk and shared resources, so collaborators can tap its antibody technology while MacroGenics gets funding and wider reach. For investors, that model can stretch capital and reduce solo development load; for partners, it offers faster access to proven science and multiple assets in one platform.

• Shared risk, shared spend
• Access to MacroGenics’ platform
• Funding plus development scale

MacroGenics, Inc. uses medical affairs to keep a steady scientific exchange with the oncology community through data sharing, congress presence, and publication support. That ongoing dialogue helps build trust around both investigational programs and any approved assets, and it supports uptake by keeping clinicians close to the latest evidence.

• Conference abstracts and presentations
• Peer-reviewed publication support
• Credibility for pipeline and approved assets

MacroGenics’ post-market safety and support centers on pharmacovigilance for MARGENZA (margetuximab-cmkb), with ongoing monitoring of infusion and cardiac risks in combination therapy. This keeps providers and patients confident that safety signals are tracked fast and product support stays active after launch.

• Track adverse events continuously
• Support combo-therapy use
• Protect trust with clinicians

MacroGenics, Inc. uses partner commercialization networks, such as Zai Lab in Greater China, to move assets into non-U.S. markets without building a full local sales force. This channel extends reach into new geographies and therapeutic areas, which is key for ex-U.S. development and commercialization.

• Uses alliance partners for market access
• Supports non-U.S. launch scale
• Reduces need for local infrastructure

MacroGenics, Inc. uses scientific publications, congress posters, and oral presentations to share preclinical and clinical data, build trust, and keep its pipeline visible. This matters most for assets with no approved label, because conference data often shapes investor and partner attention before any product sales exist.

• Use ASCO, ESMO, AACR, and ASH data
• Support pipeline credibility before approval
• Drive awareness with journal and poster readouts

Patients in oncology clinical trials are MacroGenics, Inc.'s core customer segment for studies in solid tumors and hematologic malignancies. Their enrollment helps generate clinical evidence across multiple assets and supports key readouts that can drive pipeline decisions, including response rates, safety, and progression data.

• Solid tumor and blood cancer patients
• Enable evidence across multiple assets
• Critical for pipeline advancement

MacroGenics, Inc.'s non-oncology exploratory work reaches smaller but meaningful patient pools in type 1 diabetes, autoimmune disease, and HIV-related research. That matters because the addressable market extends beyond cancer; for context, over 38 million people live with HIV worldwide, and autoimmune disease and type 1 diabetes together affect tens of millions more.

These programs are still future option value, not current scale, but they can widen the Company Name’s long-term reach if early data holds.

• Type 1 diabetes: high unmet need
• Autoimmune disease: broad patient base
• HIV: large global prevalence
• Option value beyond oncology

Selling, general, and administrative expense covers MacroGenics, Inc.'s commercial, corporate, legal, finance, and admin overhead, including Rockville headquarters costs. Even with a focused biotech and MARGENZA in market support, this base keeps the Company running and compliant.

In the latest fiscal reporting period, SG&A stayed a material cost line and helps fund field support, IP work, and public-company functions.

• Commercial support for MARGENZA
• Rockville HQ overhead
• Legal, finance, admin costs

MacroGenics, Inc. bears recurring costs for SEC filings, audit work, safety oversight, and patent upkeep, because biopharma firms must prove compliance and protect their science. U.S. patent maintenance fees alone can reach $2,150 at 3.5 years, $4,300 at 7.5 years, and $8,700 at 11.5 years per patent.

• Filings and audits keep disclosure clean.
• Safety oversight lowers trial and recall risk.
• Patent fees protect exclusivity value.

MacroGenics, Inc. can earn downstream royalties if partnered assets reach market, so revenue can scale without paying full launch, sales, or manufacturing costs. In biotech, royalty deals often run in the single-digit to low-teens percent range of net sales, which makes this a high-margin, low-capital monetization path.

• Paid only if partners commercialize
• Scales without full launch cost
• Common biotech monetization model

MacroGenics, Inc. uses research reimbursement and shared development income to shift part of R&D spend to partners, which lowers its cash burn while it advances multiple pipeline assets. For a pipeline-heavy company, this non-dilutive funding matters because it helps keep programs moving without relying only on equity or debt.

• Partner-funded R&D cuts MacroGenics' cash burden.
• Shared costs support more pipeline programs.
• Income is tied to collaboration milestones and work.